2.
治疗方案及疗效
Therapeutic regimen, scheme and outcome
| Regimen, scheme and outcome | Maintenance/Consolidation chemotherapy (n=29) | Salvage chemotherapy (n=24) | P |
| CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; MST: median survival time. | |||
| Cycle, median (range) | 2 (1-4) | 2 (1-11) | |
| Etoposide and platinum-based first-line regimen (n/%) | 28 (96.4%) | 23 (95.8%) | 0.71 |
| Topotecan treatment (n/%) | 0.06 | ||
| Topotecan | 9 (31.0%) | 14 (58.3%) | |
| Topotecan plus cisplatin | 20 (69.0%) | 10 (41.7%) | |
| Efficacy (n/%) | < 0.001 | ||
| CR | 8 (27.6%) | 0 | |
| PR | 7 (24.1%) | 10 (41.7%) | |
| SD | 5 (17.2%) | 3 (12.5%) | |
| PD | 3 (10.3%) | 6 (25.0%) | |
| Unkown | 6 (20.7%) | 5 (20.8%) | |
| Survival | |||
| 1-year | 86% | 91% | 0.78 |
| 2-year | 47% | 62% | 0.63 |
| 5-year | 19% | 5% | 0.79 |
| MST, months | 20 | 27 | 0.89 |